Principio licenses molecular imaging agents from Johns Hopkins
Principio, a developer of molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore.
The molecules include new imaging and radiotherapeutic agents for Epstein Barr Virus (EBV) associated tumors and prostate cancer, according to the Rockville, Md.-based Principio. The EBV technology, the subject of a study published in the October 2008 issue of Nature Medicine, leverages a specific enzyme produced by the virus to allow for the imaging and therapy of the tumors caused by the virus, which include numerous lymphomas, stomach cancer, nasopharyngeal cancers and most AIDS-related lymphomas.
Under the terms of the agreement, the license gives Principio exclusive, global rights to commercialize these imaging agents and therapy. Further details of the agreement were not disclosed.
The molecules include new imaging and radiotherapeutic agents for Epstein Barr Virus (EBV) associated tumors and prostate cancer, according to the Rockville, Md.-based Principio. The EBV technology, the subject of a study published in the October 2008 issue of Nature Medicine, leverages a specific enzyme produced by the virus to allow for the imaging and therapy of the tumors caused by the virus, which include numerous lymphomas, stomach cancer, nasopharyngeal cancers and most AIDS-related lymphomas.
Under the terms of the agreement, the license gives Principio exclusive, global rights to commercialize these imaging agents and therapy. Further details of the agreement were not disclosed.